Briana Contreras

First discovered in the Netherlands roughly 24 years ago, HMPV belongs to the same viral family as RSV.

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it more difficult to be treated by traditional oral antidepressants.

In a phase 2 clinical trial, researchers examined baricitinib and NB-UVB in adults with severe vitiligo in the dermatology departments at 4 hospitals in France between July 2021 and April 2023.

This ranking is based on the reviews of 12,372 consumers who evaluated their experiences with 16 major health insurance brands.

Berge will serve in this role through the end of 2026, marking another milestone in her successful career in healthcare.

Most infants born before December were administered nirsevimab, while those whose mothers reached eligible gestational age after October 25 received maternal RSVpreF.

Study authors Susan D. Reed, MD, MPH, MS, and Erin Dwyer, MPH, both at the University of Washington School of Medicine, attribute some of these different challenges to underlying health disparities.

Out of 6,540 patients involved in a study, 7.1% of those with AD had mobility impairment compared to 3.9% of those without AD.

U.S. approved the RSVpreF vaccine for adults 60 years and older in 2023, recommending it only based on individual’s decisions with their doctors.

A new, first-of-its-kind study found that these symptoms occur particularly during the late menopause transition and post-menopause.

Gastric cancer, commonly known as stomach cancer, is the fifth most common cancer globally and the fifth leading cause of cancer-related deaths.

Regenerative medicine focuses on repairing damaged skin and bringing back melanocytes, the cells that give skin its color.

Currently, the only medications approved by the FDA for PTSD are the selective serotonin reuptake inhibitors (SSRIs) sertraline and paroxetine. However, these medications don’t work for everyone.

The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce bleeding episodes in patients aged 12 and older.

Now at the highest percentage in over a decade, this number has rebounded from 42% in 2013 during the rollout of the Affordable Care Act.

Organon, the company behind Vtama, received FDA approval ahead of its scheduled date of March 12, 2025.

In past trials, ketamine intravenous treatment has shown promise, with 64% of depression patients in trials experiencing major symptom relief.

Researchers at Brigham and Women’s Hospital Harvard Medical School looked at clinical trials and compared these biologics to placebos to see how their treatments improve and manage severe asthma.

Authorities have named Mangione, 26, as a person of interest in last week’s fatal shooting of United Healthcare CEO Brian Thompson in Manhattan. He was taken into custody at a McDonald’s in Altoona, Pennsylvania around 9 a.m. ET, officials said.

Psilocybin-assisted therapy, which involves using the active ingredient from "magic mushrooms," could benefit roughly 5 million people currently receiving treatment for major depressive disorder and treatment-resistant depression if the FDA approves it.

Thompson, who was on his way to attend an annual investor conference in Manhattan today, was shot after 6:45 a.m. in a targeted attack, police officials say.

The drug has shown strong results in phase 3 clinical trials, which are the basis for the new application to the FDA.

A new nationwide study led by the Keck School of Medicine of USC aims to examine how type 1 diabetes impacts children's brain development and cognitive function, focusing on diverse participants and paving the way for early interventions and better diabetes management.

Paul Fronstin, director of Health Benefits Research at EBRI, discussed ERISA and trends in employer self-insurance during a conversation with Managed Healthcare Executive recently.

Paul Fronstin, director of Health Benefits Research at EBRI, spoke with MHE about the challenges employers face in incentivizing high-value healthcare while managing costs.

Greg Baker, CEO of AffirmedRx, shared with MHE editors how the company is addressing ongoing challenges in the pharmacy benefit management (PBM) industry, particularly corporate consolidation and transparency issues.

During the COVID-19 pandemic, healthcare workers faced several mental health challenges, experiencing repeated exposure to life-threatening situations that increased their risk of PTSD and other trauma-related conditions.

In a recent conversation with Greg Baker, CEO of AffirmedRx, the PBM professional outlined the company’s distinct approach in the PBM industry with MHE editors.

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.